TY - JOUR
T1 - Aspirin-free antiplatelet regimens after PCI
T2 - Insights from the GLOBAL LEADERS trial and beyond
AU - Wang, Rutao
AU - Wu, Sijing
AU - Gamal, Amr
AU - Gao, Chao
AU - Hara, Hironori
AU - Kawashima, Hideyuki
AU - Ono, Masafumi
AU - van Geuns, Robert-Jan
AU - Vranckx, Pascal
AU - Windecker, Stephan
AU - Onuma, Yoshinobu
AU - Serruys, Patrick W.
AU - Garg, Scot
N1 - Publisher Copyright: © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-The-Art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies.
AB - Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-The-Art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies.
KW - Aspirin-free therapy
KW - GLOBAL LEADERS
KW - P2Y12 inhibitor
KW - Percutaneous coronary intervention
KW - Randomized clinical trials
UR - http://www.scopus.com/inward/record.url?scp=85120610027&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/ehjcvp/pvab035
DO - https://doi.org/10.1093/ehjcvp/pvab035
M3 - Review article
C2 - 33930107
SN - 2055-6837
VL - 7
SP - 547
EP - 556
JO - European Heart Journal - Cardiovascular Pharmacotherapy
JF - European Heart Journal - Cardiovascular Pharmacotherapy
IS - 6
ER -